Tzu Chi Medical Journal

REVIEW ARTICLE
Year
: 2018  |  Volume : 30  |  Issue : 3  |  Page : 141--147

Treatment of acute bipolar depression


Yu-Chih Shen 
 Department of Psychiatry, Buddhist Tzu Chi General Hospital; School of Medicine, Tzu Chi University, Hualien, Taiwan

Correspondence Address:
Dr. Yu-Chih Shen
Department of Psychiatry, Buddhist Tzu Chi General Hospital, 707, Section 3, Chung-Yang Road, Hualien
Taiwan

Depression is the predominant pole of disability in bipolar disorder and compared with mania/hypomania, has less systematic research guiding the development of treatment especially in its acute phase (acute bipolar depression). The deficiency in the management of the acute bipolar depression largely reflects the natural divergence of opinion resulting from significant knowledge gaps. At present, there are only 3 approved drug treatments for acute bipolar depression: olanzapine/fluoxetine combination, quetiapine (immediate or extended release), and lurasidone (monotherapy or adjunctive to lithium or valproate). Nonapproved agents and nonpharmacologic treatment such as lamotrigine, antidepressants, modafinil, pramipexole, ketamine, and electroconvulsive therapy are often prescribed to treat acute bipolar depression. This article discusses the challenges of diagnosing bipolar depression, and reviews above treatment options for acute bipolar depression.


How to cite this article:
Shen YC. Treatment of acute bipolar depression.Tzu Chi Med J 2018;30:141-147


How to cite this URL:
Shen YC. Treatment of acute bipolar depression. Tzu Chi Med J [serial online] 2018 [cited 2021 Jan 17 ];30:141-147
Available from: https://www.tcmjmed.com/article.asp?issn=1016-3190;year=2018;volume=30;issue=3;spage=141;epage=147;aulast=Shen;type=0